[
  {
    "ts": null,
    "headline": "Will Agilent’s AI-Enabled Digital Pathology Push Reshape Agilent Technologies' (A) Diagnostics Narrative?",
    "summary": "Agilent Technologies has launched the Agilent S540MD Slide Scanner System, a high-throughput whole slide imaging scanner with AI-assisted tissue detection, now available in key European markets to support digital pathology workflows. The system, based on the Hamamatsu NanoZoomer S540MD platform but sold under the Agilent brand, broadens Agilent’s role across the pathology value chain from staining to AI-enabled decision support, giving laboratories more flexibility in how they digitize...",
    "url": "https://finnhub.io/api/news?id=8fef6e06fef4b308a9783c419d852afbbe1bcec05dd25a2b86abb46eb0a65fdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769270825,
      "headline": "Will Agilent’s AI-Enabled Digital Pathology Push Reshape Agilent Technologies' (A) Diagnostics Narrative?",
      "id": 138246884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "Agilent Technologies has launched the Agilent S540MD Slide Scanner System, a high-throughput whole slide imaging scanner with AI-assisted tissue detection, now available in key European markets to support digital pathology workflows. The system, based on the Hamamatsu NanoZoomer S540MD platform but sold under the Agilent brand, broadens Agilent’s role across the pathology value chain from staining to AI-enabled decision support, giving laboratories more flexibility in how they digitize...",
      "url": "https://finnhub.io/api/news?id=8fef6e06fef4b308a9783c419d852afbbe1bcec05dd25a2b86abb46eb0a65fdc"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time To Reconsider Agilent Technologies (A) After Recent Share Price Weakness",
    "summary": "If you are wondering whether Agilent Technologies is attractively priced right now, the key question is whether the current share price lines up with the cash flows and assets you are actually paying for. The stock closed at US$135.05 recently, with returns of a 3.3% decline over 7 days, a 2.4% decline over 30 days, a 2.1% decline year to date and a 10.1% decline over 1 year, compared with a 16.3% gain over 5 years. Recent attention on Agilent has focused on how its position in life sciences...",
    "url": "https://finnhub.io/api/news?id=8c29e4ca754134c7ecb636e58c6d18dcf898505f2ddc658073801eea521f9134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769253010,
      "headline": "Is It Time To Reconsider Agilent Technologies (A) After Recent Share Price Weakness",
      "id": 138244417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "If you are wondering whether Agilent Technologies is attractively priced right now, the key question is whether the current share price lines up with the cash flows and assets you are actually paying for. The stock closed at US$135.05 recently, with returns of a 3.3% decline over 7 days, a 2.4% decline over 30 days, a 2.1% decline year to date and a 10.1% decline over 1 year, compared with a 16.3% gain over 5 years. Recent attention on Agilent has focused on how its position in life sciences...",
      "url": "https://finnhub.io/api/news?id=8c29e4ca754134c7ecb636e58c6d18dcf898505f2ddc658073801eea521f9134"
    }
  }
]